ST Shuangcheng: Injection use paclitaxel ANDA obtained FDA approval for marketing in the United States.

ST Shuangcheng announced on the evening of May 16th that the company recently received a notification from the U.S. Food and Drug Administration (FDA). The abbreviated new drug application for injection paclitaxel submitted by the company to the FDA has been approved for marketing by the FDA. The FDA conducted a comprehensive technical review of the company's ANDA filing for injection paclitaxel and determined that the company's product is bioequivalent and therapeutically equivalent to the reference drug.